Key facts
- Inozyme Pharma, Inc. has 16 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 16 Insiders of Inozyme Pharma, Inc.
- Location
- Boston, MA
Change
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 27 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Inozyme Pharma, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Longitude Capital Partners III, LLC | 10%+ Owner | $14,902,533 | Mixed | 19 Apr 2022 | ||
| Pivotal bioVenture Partners Fund I, L.P. | Director | $5,611,115 | Mixed | 01 Aug 2023 | ||
| Henric Bjorn Bjarke | Svp, Coo | $376,424 | Mixed | 15 Dec 2022 | ||
| Matthew Winton | Coo | $184,675 | Mixed | 01 Jul 2025 | ||
| Sanjay Subramanian | SVP, CFO & Head of BD | $171,325 | Mixed | 01 Jul 2025 | ||
| Douglas A. Treco | CEO & Chairman, Director | $38,500 | Mixed | 01 Jul 2025 | ||
| Robert Lorne Hopfner | Director | $0 | Mixed | 01 Jul 2025 | ||
| Axel Bolte | Director | $0 | Mixed | 01 Jul 2025 | ||
| Lynne Marie Sullivan | Director | Mixed | 01 Jul 2025 | |||
| Erik Harris | Director | Mixed | 03 Oct 2024 | |||
| Inozyme Pharma, Inc. | Director | Mixed | 23 Jun 2021 | |||
| Mathers Edward T. | Director | Mixed | 18 Jun 2024 | |||
| Reinaldo M. Diaz | Director | Mixed | 18 Jun 2024 | |||
| Martin Edwards | Director | Mixed | 18 Jun 2024 | |||
| Sarah M. Bhagat | Director | Mixed | 18 Jun 2024 | |||
| Stephen J. DiPalma | Interim CFO | Mixed | 17 May 2021 |
Top shareholders of Inozyme Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GLAZER CAPITAL, LLC |
13D/G
|
— |
6.6%
|
4,251,940
|
$5,017,289 | $0 | 28 May 2025 | |
| BlackRock, Inc. |
13D/G
|
— |
4.1%
|
2,663,678
|
$10,654,712 | $0 | 30 Jun 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13D/G
|
— |
3.5%
|
2,220,000
|
$2,353,200 | $0 | 31 Dec 2024 | |
| Affinity Asset Advisors, LLC |
13D/G
|
Affinity Healthcare Fund, LP |
2.9%
|
1,867,710
|
$2,203,898 | $0 | 20 May 2025 | |
| Longitude Capital Partners III, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,174,379
|
$14,902,533 | — | 19 Apr 2022 | |
| Pivotal bioVenture Partners Fund I, L.P. |
3/4/5
|
Director |
—
class O/S missing
|
1,571,741
|
$5,611,115 | — | 01 Aug 2023 | |
| Henric Bjorn Bjarke |
3/4/5
|
SVP, COO |
—
class O/S missing
|
105,441
|
$376,424 | — | 15 Dec 2022 | |
| Matthew Winton |
3/4/5
|
COO | — | — | $184,675 | — | 01 Jul 2025 | |
| Sanjay Subramanian |
3/4/5
|
SVP, CFO & Head of BD | — | — | $171,325 | — | 01 Jul 2025 | |
| Douglas A. Treco |
3/4/5
|
CEO & Chairman, Director | — | — | $38,500 | — | 01 Jul 2025 | |
| Erik Harris |
3/4/5
|
Director |
—
class O/S missing
|
56,000
|
— | — | 03 Oct 2024 | |
| Martin Edwards |
3/4/5
|
Director |
—
class O/S missing
|
28,000
|
— | — | 18 Jun 2024 | |
| Mathers Edward T. |
3/4/5
|
Director |
—
class O/S missing
|
28,000
|
— | — | 18 Jun 2024 | |
| Reinaldo M. Diaz |
3/4/5
|
Director |
—
class O/S missing
|
28,000
|
— | — | 18 Jun 2024 | |
| Sarah M. Bhagat |
3/4/5
|
Director |
—
class O/S missing
|
28,000
|
— | — | 18 Jun 2024 | |
| Stephen J. DiPalma |
3/4/5
|
Interim CFO |
—
class O/S missing
|
15,000
|
— | — | 17 May 2021 | |
| Inozyme Pharma, Inc. |
3/4/5
|
Director |
—
class O/S missing
|
9,367
|
— | — | 23 Jun 2021 |
Recent Insider Transactions by Companies or Individuals for Inozyme Pharma, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sanjay Subramanian | INZY | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -39,701 | 0 | 01 Jul 2025 | Direct | ||
| Sanjay Subramanian | INZY | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -460,000 | 0 | 01 Jul 2025 | Direct | ||
| Sanjay Subramanian | INZY | Restricted Stock Units | Disposed to Issuer | -100% | -38,500 | 0 | 01 Jul 2025 | Direct | ||
| Matthew Winton | INZY | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -21,743 | 0 | 01 Jul 2025 | Direct | ||
| Matthew Winton | INZY | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -145,000 | 0 | 01 Jul 2025 | Direct | ||
| Matthew Winton | INZY | Restricted Stock Units | Disposed to Issuer | -100% | -41,500 | 0 | 01 Jul 2025 | Direct | ||
| Axel Bolte | INZY | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -423,926 | 0 | 01 Jul 2025 | Direct | ||
| Axel Bolte | INZY | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -393,363 | 0 | 01 Jul 2025 | Direct | ||
| Lynne Marie Sullivan | INZY | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -28,368 | 0 | 01 Jul 2025 | Direct | ||
| Douglas A. Treco | INZY | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -43,861 | 0 | 01 Jul 2025 | Direct | ||
| Douglas A. Treco | INZY | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -486,979 | 0 | 01 Jul 2025 | Direct | ||
| Douglas A. Treco | INZY | Restricted Stock Units | Disposed to Issuer | -100% | -150,000 | 0 | 01 Jul 2025 | Direct | ||
| Robert Lorne Hopfner | INZY | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -4,494,851 | 0 | 01 Jul 2025 | By Pivotal | ||
| Matthew Winton | INZY | Common Stock | Award | 194.3% | 14,355 | 21,743 | 25 Jun 2025 | Direct | ||
| Douglas A. Treco | INZY | Common Stock | Award | 6.86% | 2,815 | 43,861 | 25 Jun 2025 | Direct | ||
| Sanjay Subramanian | INZY | Common Stock | Award | 20.7% | 6,813 | 39,701 | 25 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.